Cryogenetics AS
ASActiveOrg 985283885Storhamargata 44, 2317 HamarResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2002 · 23 years old27 employeeshttps://www.cryogentics.no
Loading company…
Overview
Cryogenetics AS is a Norwegian AS based in Hamar, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2002, the company has 27 employees and reported revenue of NOK 36.6m in its latest annual filing.
Revenue 2025
36.6M NOK
+6% vs 2024
EBITDA margin
20.4 %
+414% vs 2024
Net profit 2025
3.7M NOK
+186% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
55.5 %
AverageAround the average of companies in the same industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
2.4×
AverageAround the average of companies in the same industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
5.5 %
AverageAround the average of companies in the same industry
20212025
EBITDA — year on year
NOK millionsKey figures
Annual report 2025| Revenue | 36.6M NOK | +6% |
| EBITDA | 7.5M NOK | +414% |
| Net profit | 3.7M NOK | +186% |
| Total assets | 68.2M NOK | +27% |
| Equity | 37.9M NOK | +11% |
| Employees | 27 | — |
Company information
Legal name
CRYOGENETICS AS
Org number
985283885
Legal form
Aksjeselskap
Founded
4 December 2002 · 23 years
Share capital
NOK 4,428,320
Employees
27 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Daglig leder og ett styremedlem i fellesskap.
Company purpose
Å drive utvikling og salg av produkter og tjenester tilknyttet behandling av melke, frysing og lagring av genetisk materiale fra akvatiske organismer og naturlig tilhørende virksomhet.
(no translation available)
Contact
Address
Storhamargata 44, 2317 Hamar
Website
https://www.cryogentics.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), Cryogenetics AS reported revenue of NOK 36.6m, an increase of 6% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of NOK 3.7m, and the EBITDA margin stood at 20.4%.
At the end of 2025, equity financed 55.5% of the balance sheet, and current assets covered short-term debt 2.4 times.
Financials
Revenue
NOK millionsEBITDA
NOK millionsIncome statement
NOK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 36,616 | 34,694 | 32,654 | 22,836 | 20,769 |
| Staff expenses | -13,127 | -21,190 | -8,646 | -8,159 | -7,156 |
| EBITDA | 7,473 | -2,378 | 10,336 | 1,617 | 3,999 |
| Depreciation & amort. | -3,513 | -3,405 | -2,351 | -1,695 | -1,534 |
| EBIT | 3,960 | -5,782 | 7,985 | -78 | 2,465 |
| Net financials | 529 | -127 | -482 | 733 | 1,231 |
| Profit before tax | 4,489 | -5,910 | 7,503 | 655 | 3,696 |
| Tax | 766 | -1,590 | 1,446 | -52 | 611 |
| Net profit | 3,723 | -4,320 | 6,057 | 707 | 3,085 |
Balance sheet
NOK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 68,160 | 53,464 | 56,509 | 51,234 | 46,279 |
| Equity | 37,851 | 34,127 | 38,447 | 32,390 | 31,683 |
| Long-term debt | 20,266 | 9,558 | 11,085 | 10,252 | 9,331 |
| Short-term debt | 10,043 | 9,778 | 6,977 | 8,591 | 5,168 |
| Total debt | 30,309 | 19,336 | 18,062 | 18,843 | 14,499 |
Financial ratios
5-year trendEBITDA margin
20.4 %
20212025
Equity ratio
55.5 %
AverageAround the average of companies in the same industry
20212025
Return on equity
9.8 %
AverageAround the average of companies in the same industry
20212025
Net profit margin
10.2 %
AverageAround the average of companies in the same industry
20212025
Asset turnover
0.54×
AverageAround the average of companies in the same industry
20212025
Debt / equity
0.80×
AverageAround the average of companies in the same industry
20212025
Sector performance
28 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Gross marginWeak
Among the 30% lowest rated companies in the industry
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginAverage
Around the average of companies in the same industry
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginAverage
Around the average of companies in the same industry
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Average
Around the average of companies in the same industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Average
Around the average of companies in the same industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Strong
Among the 40% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioStrong
Among the 40% highest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioAverage
Around the average of companies in the same industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioAverage
Around the average of companies in the same industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioAverage
Around the average of companies in the same industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityStrong
Among the 30% highest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalWeak
Among the 40% lowest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioVery strong
Among the 10% highest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioAverage
Around the average of companies in the same industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioAverage
Around the average of companies in the same industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityAverage
Around the average of companies in the same industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityAverage
Around the average of companies in the same industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtAverage
Around the average of companies in the same industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtStrong
Among the 40% highest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageAverage
Around the average of companies in the same industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery weak
Among the 20% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginAverage
Around the average of companies in the same industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Asset turnoverAverage
Around the average of companies in the same industry
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverWeak
Among the 40% lowest rated companies in the industry
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Equity to contributed capitalAverage
Around the average of companies in the same industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityStrong
Among the 40% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtWeak
Among the 30% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Annual reports & filings
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ES Chief Executive Officer | Chief Executive Officer | 2017 |
Former (2)
PS Deputy Member | Deputy Member | 2021 – 2024 |
RV Observer | Observer | 2024 – 2026 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
AA Board of Directors | Board of Directors | 2024 |
KW Board of Directors | Board of Directors | 2025 |
OS Chairman | Chairman | 2024 |
KH Board of Directors | Board of Directors | 2024 |
Former (4)
TA Board of Directors | Board of Directors | 2021 – 2024 |
KM Board of Directors | Board of Directors | 2021 – 2024 |
ES Chairman | Chairman | 2021 – 2024 |
RV Board of Directors | Board of Directors | 2021 – 2024 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 50% | 50% | 2020 | |
| Company | 37.25% | 37.25% | 2020 | |
| Company | 12.75% | 12.75% | 2020 |
Related companies
Company hierarchy
Investinor Direkte As
Cryogenetics AS Board network connections
Board members of Cryogenetics AS also hold positions in 177 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Alf-Helge Aarskog | Board of Directors | 46 companiesMany roles |
| Kjetil Haga | Board of Directors | 34 companiesMany roles |
| Even Søfteland | Chairman | 28 companiesMany roles |
| Karina Wessel | Board of Directors | 17 companiesMany roles |
| Eli Sætersmoen | Chief Executive Officer | 11 companiesMany roles |
| Pål Sommer Breiland | Deputy Member | 9 companiesMany roles |
| Torbjørn Almlid | Board of Directors | 9 companiesMany roles |
| Otto Søberg | Chairman | 9 companiesMany roles |
| Ronny Vikdal | Observer | 7 companiesMany roles |
| Kristin Malonæs | Board of Directors | 7 companiesMany roles |
Frequently asked questions
What is the Org number of Cryogenetics AS?
Cryogenetics AS is registered with Brønnøysundsregistrene under Org 985283885.
What is the revenue of Cryogenetics AS?
Cryogenetics AS reported revenue of NOK 36.6m in 2025.
How many employees does Cryogenetics AS have?
Cryogenetics AS employs 27 people as of the latest annual report.
Who is the CEO of Cryogenetics AS?
Eli Sætersmoen is the CEO of Cryogenetics AS, in role since 2017.
Who is the chairman of Cryogenetics AS?
Otto Søberg chairs the board of Cryogenetics AS, in role since 2024.
Where is Cryogenetics AS headquartered?
Cryogenetics AS's registered address is Storhamargata 44.